Maalox Problems Could Occur Due to Product Confusion

The FDA is requiring Novartis Consumer Health, Inc. to change the name of one of its Maalox products due to label confusion that could cause consumers to use the wrong type of medication, potentially leading to harmful Maalox side effects.

In a statement issued Wednesday, the FDA warned about the risk of Maalox problems and announced that Novartis will change the name and label of Maalox Total Relief to avoid confusion with other Maalox products, such as Maalox Advanced Regular Strength and Maalox Advanced Maximum Strength. Maalox Total Relief is a medication intended to treat upset stomachs, nausea and diarrhea, whereas other Maalox products are sold as antacids.

The over-the-counter medications have entirely different active ingredients, with Maalox Total Relief (bismuth subsalicylate) being similar to aspirin. The FDA says that it is concerned that consumers will mistakenly take Maalox Total Relief, thinking that it is an antacid, which could lead to problems from Maalox for some users.

Did You Know?

AT&T Data Breach Impacts Millions of Customers

More than 73 million customers of AT&T may have had their names, addresses, phone numbers, Social Security numbers and other information released on the dark web due to a massive AT&T data breach. Lawsuits are being pursued to obtain financial compensation.

Regular Maalox products have the active ingredients of aluminum hydroxide, magnesium hydroxide and simethicone. They are intended for the relief of acid indigestion, heartburn and gas.

Maalox Total Relief is not appropriate for individuals with a history of gastrointestinal ulcer disease or a bleeding disorder,’” the FDA warned in a press release. “Maalox Total Relief also should not be taken by children and teens if they are recovering from a viral infection, nor by individuals who are taking certain medications including: oral antidiabetic drugs (OADs), anticoagulation (thinning the blood) drugs such as warfarin (Coumadin) and clopidogrel (Plavix), non-steroidal anti-inflammatory drugs (NSAIDS), and other anti-inflammatory drugs.”

The FDA says Novartis has agreed to change the name of Maalox Total Relief to a new name that does not include the word Maalox, and will also change the label design, which is currently nearly identical to Maalox antacid products. In addition, the company will conduct an educational campaign to highlight the differences between the products for healthcare professionals and consumers.

Novartis will also monitor for adverse events and side effects caused by consumers mistakenly taking Maalox Total Relief when they intended to take one of the company’s antacid products. The new, renamed product will be released in September 2010.

1 Comments

  • MarcellaOctober 27, 2020 at 4:58 am

    I wish I had known this sooner, my mother dark maylox stait from the bottle for "heartburn" years and died from pancreatic cancer in Dec of 1990, I was prescribed PRILOCEC And levsin after my gallbladder surgery in Feb. 2015" and now they have my 15 yr old daughter on PRILOCEC and Zofran since she was 13?

Share Your Comments

I authorize the above comments be posted on this page*

Want your comments reviewed by a lawyer?

To have an attorney review your comments and contact you about a potential case, provide your contact information below. This will not be published.

NOTE: Providing information for review by an attorney does not form an attorney-client relationship.

This field is for validation purposes and should be left unchanged.

More Top Stories

Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery
Uber Driver Sexual Assaults and Misconduct Reports Must Be Disclosed in Lawsuit Discovery (Posted today)

A federal magistrate judge is forcing Uber to hand over potentially hundreds of thousands of incident files involving reports of passengers who suffered sexual misconduct or sexual assault at the hands of the rideshare service's drivers.

Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits
Abbott May Remove Infant Formula for Preemies Off the Market Due to Similac NEC Lawsuits (Posted yesterday)

Abbott Laboratories is considering removing Similac infant formula products designed for preterm babies from the market, as it faces hundreds of lawsuits claiming the products increase the risk of necrotizing enterocolitis, which puts newborns at a high risk of permanent injuries and death.

Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL
Information About Suboxone Dental Claims To Be Exchanged By Parties in MDL (Posted 2 days ago)

A federal judge has ordered parties involved in Suboxone dental decay lawsuits to submit proposals for exchanging information that will guide the selection of representative bellwether claims for early test trials.